The Wien Center for Alzheimer's Disease and Memory Disorders,
Mount Sinai Medical Center, Miami Beach presents:

11th Mild Cognitive Impairment Symposium

2nd Early Alzheimer's Diagnostic and Treatment Workshop

1st Alzheimer’s Public Educational Forum

January 19 – 20, 2013   Miami, Florida, USA

  HOME

  GENERAL INFORMATION

  PROGRAM

  SPEAKERS

  ACCREDITATION

  SCHOLARSHIPS

  REGISTRATION

  VENUE/ACCOMMODATIONS

  SUPPORTERS

  CONTACT

COURSE PROGRAM

 

Program Director:
Ranjan Duara, MD
Medical Director, Wien Center for Alzheimer's Disease and Memory Disorders
Mount Sinai Medical Center
Miami Beach, FL

Full list of our speakers


Mild Cognitive Impairment (MCI) Symposium 2013

Predicting and Measuring Progression in Early Alzheimer's Disease (AD)

Saturday, JANUARY 19, 2013
7:00 am – 7:30 pm

7:00 – 8:00 am Breakfast Buffet
8:00 – 8:15 am Welcome and Introduction Ranjan Duara, MD
Mount Sinai Medical Center,
Miami Beach, FL
8:15 – 10:45 am Mini – Symposium 1
Predictors of Progression to MCI and AD (Epidemiology)
Chair: Mary Ganguli, MD, MPH, University of Pittsburgh, Pittsburgh, PA
1. New Approaches to Understanding the Relationships of Risk Factors to Cognitive Decline David A. Bennett, MD
Rush Medical School,
Chicago, IL
2. The Flynn Effect; How Secular Changes Influence the Predictive Value of Cognitive Performance and the Role of Computer Tomography in Prodromal Dementia in the H70 Study in Gothenburg, Sweden Simona Sacuiu, MD, PhD
Sahlgrenska Academy, University of Gothenburg,
Gothenburg, Sweden
3. Rates and Predictors of Progression from Mild Cognitive Impairment to Dementia: The Mayo Clinic Study of Aging Rosebud Roberts, MB, ChB
Mayo Clinic,
Rochester, MN
4. Risk Factors for Age of Onset of AD in the Cache County Study Peter Rabins, MD, MPH
Johns Hopkins University,
Baltimore, MD
5. The Fluidity of MCI in the Community and the Role of Vascular Biomarkers in Predicting Progression in the Indianapolis-Ibadan Study Hugh Hendrie, MB, ChB, DSc
Indiana University,
Indianapolis, IN
6. Risk Factors for MCI Development and for MCI Progression: Are They The Same? Mary Ganguli, MD, MPH
University of Pittsburgh,
Pittsburgh, PA
10:45 – 11 am Break
11:00 am – Noon Open Discussion
Discussant: Ronald Petersen, MD, PhD, Mayo Clinic, Rochester, MN
Noon – 1 pm LUNCH
1:00 – 2:00 pm Keynote Lecture:
Solving the Dilemma of Treatment Versus Prevention Strategies for Alzheimer's Disease
Todd Golde, MD, PhD, University of Florida, Gainesville, FL
2:00 – 4:15pm Mini – Symposium 2
Utility of Biomarkers for Predicting and Measuring Progression in Normal Aging, MCI and AD
Chair: Tammie Benzinger, MD, PhD, Washington University School of Medicine, St. Louis, MO
1. The Cortical Signatures of Alzheimer's Disease and Frontotemporal Degeneration: Quantitative MRI Biomarkers Detectable prior to Dementia Brad Dickerson, MD, MMSc
Harvard Medical School,
Boston, MA
2. Biomarkers, Cognitive Reserve and Cognition in Alzheimer's Disease Prashanthi Vemuri, PhD
Mayo Clinic,
Rochester, MN
3. Neuroimaging for Predicting and Measuring Progression in Preclinical Autosomal Dominant Alzheimer's Disease Tammie Benzinger, MD, PhD
Washington University School of Medicine,
St. Louis, MO
4. MRI, FDG-PET and EEG for Predicting Progression in Aging, MCI and AD Philip Scheltens, MD, PhD
VU Medical Center,
Amsterdam, Netherlands
5. Highlights of Biomarker and Clinical Outcomes from Recent AD Treatment Trials Stephen Salloway, MD, MS
Brown Medical School,
Providence, RI
4:15 – 4:30 Break
4:30 – 5:30 pm Open Discussion
Discussant: Victor Villemagne, MD, Austin Health, University of Melbourne, Melbourne, Australia
5:30 – 7:30 pm NETWORKING RECEPTION

Early Alzheimer's Disease Workshop

Alzheimer's Disease Prevention Trials

Sunday, JANUARY 20, 2013
8:00 am – 1:30 pm

7:00 – 8:00 am Breakfast Buffet
8:00 am – 8:10 Introduction to the Workshop Ranjan Duara, MD
Mount Sinai Medical Center,
Miami Beach, FL
8:10 – 9:00 am Keynote Lecture:
Launching the Era of Alzheimer's Prevention Research
Eric M. Reiman, MD
Banner Alzheimer's Institute,
Phoenix, AZ
9:00 – 11:15am Challenges in Treating Preclinical Alzheimer's Disease
Chair: Reisa A. Sperling, MD, MMSc, Massachusetts General Hospital and Harvard Medical School, Boston, MA
1. A New Era: DIAN and the Secondary Prevention of Symptomatic Alzheimer's Disease John C. Morris, MD
Washington University School of Medicine,
St. Louis, MO
2. Anti-Amyloid Treatment of Asymptomatic Alzheimer's Disease: The A4 Study Reisa A. Sperling, MD, MMSc,
Massachusetts General Hospital and Harvard Medical School,
Boston, MA
3. The Role of Fluid Biomarkers in Preclinical Alzheimer's Treatment Trials Anne M. Fagan, PhD
Washington University School of Medicine,
St. Louis, MO
4. The Role of Amyloid Imaging in Preclinical Alzheimer's Treatment Trials Adam S. Fleisher, MD, MAS
Banner Alzheimer's Institute,
Phoenix, AZ
5. Addressing the Ethical Challenges of Preclinical AD Prevention Trials Jason Karlawish, MD
University of Pennsylvania School of Medicine,
Philadelphia, PA
6. Consent for Revealing Biomarker Status in AD Prevention Trials Scott Roberts, PhD
University of Michigan School of Public Health,
Ann Arbor, MI
11:15am – 11:30 Break
11:30am – 12:30 pm Open Discussion
Discussant: Philip Scheltens, MD, PhD VU Medical Center, Amsterdam, Netherlands
 
12:30 – 1:30 pm LUNCH  

Alzheimer's Public Educational Forum

Alzheimer's Disease Prevention Trials

Sunday, JANUARY 20, 2013
2:00 pm – 5:30 pm
Chair: Eric M. Reiman, MD, Banner Alzheimer's Institute, Phoenix, AZ

2:00 – 2:10 pm Introduction to the Educational Forum Ranjan Duara, MD
Mount Sinai Medical Center,
Miami Beach, FL
2:10 – 4:30 pm Measuring Progression in Alzheimer's Disease Using Brain Imaging Tests Susan Landau, PhD
University of California,
Berkeley, CA
Questions and Answers
Treating Alzheimer's Before Symptoms Begin Reisa A. Sperling, MD, MMSc,
Massachusetts General Hospital and Harvard Medical School,
Boston, MA
Questions and Answers
What We Know About the Genetics of Alzheimer's Disease Allan Levey, MD, PhD
Emory University School of Medicine,
Atlanta, GA
Questions and Answers
The Importance of Being Informed and Participating in Trials Maria Carillo, PhD
Alzheimer's Association,
Chicago, IL
Questions and Answers
4:30 – 5:30 pm Questions from the Audience and Panel Discussion
Panelists: Maria Carillo, John C. Morris, Steve Salloway, Eric Reiman, Reisa A. Sperling, Scott Roberts
 

 

CONTACT

Conference Secretariat:
 
Tel: +1.224.938.9523
 
Fax: +1.312.278.0787
 
  TOP
-